GB Sciences, Inc. (GBLX)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.74 Million USD | 35.85% |
| 2022 | 1.28 Million USD | 11.75% |
| 2021 | 1.15 Million USD | -68.59% |
| 2020 | 3.66 Million USD | -60.45% |
| 2019 | 9.26 Million USD | 9.55% |
| 2018 | 8.45 Million USD | 112.79% |
| 2017 | 3.97 Million USD | 221.45% |
| 2016 | 1.23 Million USD | -52.03% |
| 2015 | 2.57 Million USD | 8490.88% |
| 2014 | 30 Thousand USD | -96.77% |
| 2013 | 928.11 Thousand USD | 39.03% |
| 2012 | 667.57 Thousand USD | -10.73% |
| 2011 | 747.82 Thousand USD | -11.22% |
| 2010 | 842.3 Thousand USD | 26.14% |
| 2009 | 667.74 Thousand USD | 129.49% |
| 2008 | 290.96 Thousand USD | 8897.16% |
| 2007 | 3234.00 USD | -97.39% |
| 2006 | 123.9 Thousand USD | 197.22% |
| 2005 | 41.68 Thousand USD | 534.75% |
| 2004 | -9589.00 USD | -188.9% |
| 2003 | 10.78 Thousand USD | 169.81% |
| 2002 | -15.45 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | 1.74 Million USD | 16.89% |
| 2023 FY | 1.74 Million USD | 35.85% |
| 2023 Q2 | 1.39 Million USD | -0.67% |
| 2023 Q3 | 1.49 Million USD | 7.0% |
| 2023 Q1 | 1.4 Million USD | 9.36% |
| 2022 Q3 | 1.12 Million USD | 53.22% |
| 2022 Q1 | 1.33 Million USD | 15.9% |
| 2022 Q4 | 1.28 Million USD | 14.71% |
| 2022 Q2 | 731.76 Thousand USD | -45.15% |
| 2022 FY | 1.28 Million USD | 11.75% |
| 2021 Q1 | 3.42 Million USD | -6.47% |
| 2021 FY | 1.15 Million USD | -68.59% |
| 2021 Q4 | 1.15 Million USD | 172.23% |
| 2021 Q2 | 3.72 Million USD | 8.69% |
| 2021 Q3 | 422.79 Thousand USD | -88.65% |
| 2020 Q2 | 9.34 Million USD | -13.15% |
| 2020 Q4 | 3.66 Million USD | 2.6% |
| 2020 FY | 3.66 Million USD | -60.45% |
| 2020 Q1 | 10.76 Million USD | 16.18% |
| 2020 Q3 | 3.57 Million USD | -61.8% |
| 2019 Q2 | 8.76 Million USD | -20.93% |
| 2019 Q1 | 11.07 Million USD | 31.0% |
| 2019 Q3 | 9.16 Million USD | 4.56% |
| 2019 Q4 | 9.26 Million USD | 1.13% |
| 2019 FY | 9.26 Million USD | 9.55% |
| 2018 Q2 | 4.56 Million USD | 53.38% |
| 2018 FY | 8.45 Million USD | 112.79% |
| 2018 Q4 | 8.45 Million USD | 14.15% |
| 2018 Q3 | 7.4 Million USD | 62.39% |
| 2018 Q1 | 2.97 Million USD | -25.16% |
| 2017 Q2 | 5.74 Million USD | 129.88% |
| 2017 Q1 | 2.49 Million USD | 102.03% |
| 2017 FY | 3.97 Million USD | 221.45% |
| 2017 Q4 | 3.97 Million USD | -30.92% |
| 2017 Q3 | 5.75 Million USD | 0.19% |
| 2016 Q2 | 4.63 Million USD | 97.86% |
| 2016 FY | 1.23 Million USD | -52.03% |
| 2016 Q1 | 2.34 Million USD | -9.14% |
| 2016 Q4 | 1.23 Million USD | -67.89% |
| 2016 Q3 | 3.85 Million USD | -16.89% |
| 2015 Q1 | -332.78 Thousand USD | -1209.29% |
| 2015 Q4 | 2.57 Million USD | 24.08% |
| 2015 Q2 | 1.24 Million USD | 473.76% |
| 2015 Q3 | 2.07 Million USD | 66.99% |
| 2015 FY | 2.57 Million USD | 8490.88% |
| 2014 Q1 | -2.83 Million USD | -405.97% |
| 2014 FY | 30 Thousand USD | -96.77% |
| 2014 Q4 | 30 Thousand USD | 110.82% |
| 2014 Q3 | -277.14 Thousand USD | 83.03% |
| 2014 Q2 | -1.63 Million USD | 42.49% |
| 2013 Q1 | 667.59 Thousand USD | 0.0% |
| 2013 Q3 | 624.72 Thousand USD | 13.75% |
| 2013 Q2 | 549.2 Thousand USD | -17.73% |
| 2013 Q4 | 928.11 Thousand USD | 48.56% |
| 2013 FY | 928.11 Thousand USD | 39.03% |
| 2012 Q3 | 546 Thousand USD | -8.57% |
| 2012 Q1 | 584.59 Thousand USD | -21.83% |
| 2012 Q2 | 597.16 Thousand USD | 2.15% |
| 2012 Q4 | 667.57 Thousand USD | 22.27% |
| 2012 FY | 667.57 Thousand USD | -10.73% |
| 2011 Q4 | 747.82 Thousand USD | -23.64% |
| 2011 Q2 | 970.57 Thousand USD | -5.52% |
| 2011 Q3 | 979.33 Thousand USD | 0.9% |
| 2011 FY | 747.82 Thousand USD | -11.22% |
| 2011 Q1 | 1.02 Million USD | 21.96% |
| 2010 FY | 842.3 Thousand USD | 26.14% |
| 2010 Q4 | 842.3 Thousand USD | -10.66% |
| 2010 Q1 | 888.76 Thousand USD | 33.1% |
| 2010 Q2 | 929.9 Thousand USD | 4.63% |
| 2010 Q3 | 942.77 Thousand USD | 1.38% |
| 2009 Q4 | 667.74 Thousand USD | 18.6% |
| 2009 FY | 667.74 Thousand USD | 129.49% |
| 2009 Q3 | 563.02 Thousand USD | 48.57% |
| 2009 Q2 | 378.96 Thousand USD | 21.34% |
| 2009 Q1 | 312.3 Thousand USD | 7.33% |
| 2008 Q3 | 256.04 Thousand USD | 6.9% |
| 2008 Q4 | 290.96 Thousand USD | 13.64% |
| 2008 Q1 | 2819.00 USD | -12.83% |
| 2008 Q2 | 239.52 Thousand USD | 8396.7% |
| 2008 FY | 290.96 Thousand USD | 8897.16% |
| 2007 FY | 3234.00 USD | -97.39% |
| 2007 Q4 | 3234.00 USD | -97.48% |
| 2007 Q3 | 128.09 Thousand USD | 16.6% |
| 2007 Q2 | 109.86 Thousand USD | 236.86% |
| 2007 Q1 | -80.27 Thousand USD | -164.79% |
| 2006 Q2 | 217.25 Thousand USD | 361.54% |
| 2006 Q3 | 176.2 Thousand USD | -18.9% |
| 2006 FY | 123.9 Thousand USD | 197.22% |
| 2006 Q4 | 123.9 Thousand USD | -29.68% |
| 2006 Q1 | 47.07 Thousand USD | 12.92% |
| 2005 Q4 | 41.68 Thousand USD | -69.96% |
| 2005 Q3 | 138.77 Thousand USD | 0.0% |
| 2005 FY | 41.68 Thousand USD | 534.75% |
| 2005 Q2 | - USD | -100.0% |
| 2005 Q1 | 74.05 Thousand USD | 872.3% |
| 2004 Q1 | 22.09 Thousand USD | 104.83% |
| 2004 Q4 | -9589.00 USD | -102.99% |
| 2004 FY | -9589.00 USD | -188.9% |
| 2004 Q2 | 128.26 Thousand USD | 480.59% |
| 2004 Q3 | 320.37 Thousand USD | 149.77% |
| 2003 Q3 | -60.00 USD | 79.87% |
| 2003 Q1 | -5526.00 USD | 64.24% |
| 2003 Q2 | -298.00 USD | 94.61% |
| 2003 Q4 | 10.78 Thousand USD | 18076.67% |
| 2003 FY | 10.78 Thousand USD | 169.81% |
| 2002 Q2 | -4491.00 USD | 0.58% |
| 2002 Q4 | -15.45 Thousand USD | -295.07% |
| 2002 Q1 | -4517.00 USD | 0.0% |
| 2002 FY | -15.45 Thousand USD | 0.0% |
| 2002 Q3 | -3911.00 USD | 12.91% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 133482.901% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 69.065% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 95.917% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 799.99% |
| Rebus Holdings, Inc. | 305 Thousand USD | -472.89% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 127.715% |
| Qrons Inc. | 351.42 Thousand USD | -397.206% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | -180.755% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 95.977% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 8661.917% |
| Skye Bioscience, Inc. | -5.72 Million USD | 130.54% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 88.915% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 57.569% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -334.819% |
| SQZ Biotechnologies Company | -36.23 Million USD | 104.822% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 22.073% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | -88.454% |
| Mesoblast Limited | 55.85 Million USD | 96.872% |
| Marizyme, Inc. | 18.56 Million USD | 90.59% |
| Genus plc | 190.6 Million USD | 99.083% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 21.849% |
| Pharming Group N.V. | 109.8 Million USD | 98.409% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | -103.119% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | -43.944% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | -156.958% |
| ContraFect Corporation | -6.02 Million USD | 128.996% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -1197.779% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | -51.227% |
| IMV Inc. | 7.67 Million USD | 77.22% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 68.242% |
| MultiCell Technologies, Inc. | 90.04 USD | -1940499.733% |
| ONE Bio Corp. | 9.04 Million USD | 80.671% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 338.061% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 86.503% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | -27.73% |
| Q BioMed Inc. | 4.06 Million USD | 56.963% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 94.281% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | -73.394% |
| Biomind Labs Inc. | 711.4 Thousand USD | -145.616% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 97.114% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 12.608% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 86.356% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -385.757% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -1149.833% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -8695.067% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 20.648% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 1050.724% |
| HST Global, Inc. | 96.79 Thousand USD | -1705.209% |
| CSL Limited | 10.52 Billion USD | 99.983% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | -747.319% |
| Halberd Corporation | 144.72 Thousand USD | -1107.369% |
| Enzolytics Inc. | 981.65 Thousand USD | -77.997% |
| Agentix Corp. | 37.63 Thousand USD | -4543.289% |
| Resverlogix Corp. | 6.45 Million USD | 72.914% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 359.597% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.086% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 103.717% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 75.289% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 35.49% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 119.766% |
| AVAX Technologies, Inc. | -5.9 Million USD | 129.599% |
| Zenith Capital Corp. | 10.06 Thousand USD | -17262.043% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.165% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | -771.775% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 26.769% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | -962.14% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 9638.792% |
| Kadimastem Ltd | -253.1 Thousand USD | 790.36% |
| Helix BioMedix, Inc. | -2.57 Million USD | 167.988% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 91.382% |
| BioStem Technologies, Inc. | 4.47 Million USD | 60.928% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | -768.214% |
| LadRx Corporation | -2.03 Million USD | 185.801% |
| Cell Source, Inc. | 9.23 Million USD | 81.073% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -175.096% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | -175.096% |
| NovAccess Global Inc. | 2.17 Million USD | 19.791% |
| Affymax, Inc. | -5.59 Million USD | 131.219% |
| Itoco Inc. | 228.3 Thousand USD | -665.343% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -1184.895% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 64.751% |
| Mobile Lads Corp. | 484.23 Thousand USD | -260.843% |
| CytoDyn Inc. | 20.26 Million USD | 91.376% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 270164.297% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 18952.524% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 77.325% |
| SYBLEU INC | 473.71 Thousand USD | -268.855% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 60.796% |
| International Stem Cell Corporation | 2.59 Million USD | 32.536% |
| Bioxytran, Inc. | 1.89 Million USD | 7.983% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -2699.603% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 19.881% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 49.117% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 79.571% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | -126.158% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 239.785% |
| Neutra Corp. | 52.18 Thousand USD | -3248.182% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 170.202% |
| PureTech Health plc | -167.19 Million USD | 101.045% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 813.458% |
| IXICO plc | -4.44 Million USD | 139.313% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 86.782% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 96.814% |
| CSL Limited | 10.52 Billion USD | 99.983% |
| Cellectis S.A. | -43.81 Million USD | 103.988% |